Hyperbaric Oxygen Therapy for Cerebral Radiation Necrosis Secondary to Stereotactic Radiation: A Case Series

Sruti Prathivadhi-Bhayankaram
University of Iowa Hospitals and Clinics

jeffrey S. cooper
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/gmerj

Part of the Higher Education Commons, and the Therapeutics Commons

Recommended Citation
https://digitalcommons.unmc.edu/gmerj/vol4/iss1/7

This Original Report is brought to you for free and open access by DigitalCommons@UNMC. It has been accepted for inclusion in Graduate Medical Education Research Journal by an authorized editor of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.
Hyperbaric Oxygen Therapy for Cerebral Radiation Necrosis Secondary to Stereotactic Radiation: A Case Series

Abstract

Introduction: Stereotactic radiosurgery (SRS) is an excellent option for the treatment of numerous central nervous system diseases. There exist several forms of SRS, including gamma-knife surgery (GKS) and cyber-knife surgery. The most significant complication of SRS is the delayed effects of therapeutic radiation, also known as radionecrosis. The current treatment options for radionecrosis have a significant side effect profile and posit challenges for medical management. More recently, hyperbaric oxygen therapy (HBO2) has emerged as an option for treatment with minimal side effects.

Methods: We present a retrospective case series examining ten patients treated with HBO2 after receiving radiotherapy. Of these cases, six were treated with GKS, two were treated with cyber-knife surgery, and two with intensity-modulated radiation therapy (IMRT).

Results: In all ten cases, the patients reported significant improvement in clinical symptoms.

Conclusions: These cases demonstrate the efficacy of HBO2 as a treatment for cerebral radionecrosis.

Keywords
Hyperbaric oxygen therapy, stereotactic radiation, cyber-knife surgery, gamma-knife surgery, cerebral necrosis

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Hyperbaric Oxygen Therapy for Cerebral Radiation Necrosis Secondary to Stereotactic Radiation: A Case Series

Sruti Prathivadhi-Bhayankaram, Jeffrey S. Cooper

1University of Iowa, Hospitals and Clinics, Department of Internal Medicine
2University of Nebraska Medical Center, College of Medicine, Department of Emergency Medicine

Abstract

Introduction: Stereotactic radiosurgery (SRS) is an excellent option for the treatment of numerous central nervous system diseases. There exist several forms of SRS, including gamma-knife surgery (GKS) and cyber-knife surgery. The most significant complication of SRS is the delayed effect of therapeutic radiation, also known as radionecrosis. The current treatment options for radionecrosis have a significant side effect profile and posit challenges for medical management. More recently, hyperbaric oxygen therapy (HBO2) has emerged as an option for treatment with minimal side effects.

Methods: We present a retrospective case series examining ten patients treated with HBO2 after receiving radiotherapy. Of these cases, six were treated with GKS, two were treated with cyber-knife surgery, and two with Intensity-modulated radiation therapy (IMRT).

Results: In all ten cases, the patients reported significant improvement in clinical symptoms.

Conclusions: These cases demonstrate the efficacy of HBO2 as a treatment for cerebral radionecrosis.

Introduction

Hyperbaric oxygen therapy (HBO2) involves breathing pressurized oxygen in a chamber to increase blood oxygen levels and improve cellular repair mechanisms. This therapy has been used for complications of radiation treatment and certain non-healing wounds. However, there are limited reports on the use of HBO2 in treating cerebral necrosis due to late radiation effects. Our study aims to demonstrate the efficacy and role of HBO2 in treating cerebral radiation necrosis by discussing several patients in a case series.

Although more known for treating infections and decompression sickness, HBO2 has previously been used for various cerebral complications. HBO2 has been used for cases of acute stroke, spinal cord injuries, meningitis, cerebral abscesses, and cerebral edema. HBO2 has also been used as prophylaxis and treatment for radiation myelitis. More recently, HBO2 has also been used to treat sequelae of radiation therapy to the brain in a manner similar to its use in treating other soft tissue and bony radionecrosis.

In reviewing the current literature, there are a few reported cases of HBO2 in treating acute radiation effects after stereotactic radiation for AVMs. These reports showed resolution of cerebral edema and hemiparesis. These reports demonstrate that HBO2 may be a minimally invasive option for treating radiation necrosis and acute post-treatment edema. However, many of these cases strictly consider gamma-knife surgery (GKS) and fail to account for other forms of radiation therapy. The outcomes are variable, with inconsistent results across cases. Other studies describe the use of HBO2 in radiation-induced necrosis by monitoring outcomes in terms of clinical and radiological improvement. However, these reports are few, and a more extensive reservoir of data is needed to establish the role of HBO2.

Our study adds to current data by considering central nervous system injury cases secondary to stereotactic radiation by CyberKnife, GKS, and intensity-modulated radiation therapy (IMRT). HBO2 can be an efficacious treatment for late radiation effects on the brain, and our case series aids in establishing its role in this landscape.

Methods

This case series is a retrospective analysis of ten patients with post-radiation central nervous system injury at a tertiary care hospital’s hyperbaric unit. Patients received hyperbaric oxygen with various protocols ranging from ninety minutes at 2.0-2.4 ATA and ranging from 8 to 60 treatments.

The University’s Institutional Review Board approved this study (0101-21-EP). Electronic chart records from the hyperbaric unit were obtained. Patients were selected based on central nervous system injury after radiation treatment. A chart review of the ten patients was conducted, noting their diagnosis, the type and amount of radiation, hyperbaric oxygen treatment, and clinical outcome. Pre- and post-clinical assessments were reviewed, as were radiological findings when available. A review of our results may be found in Table 1.

Case Descriptions

Case 1

A 19-year-old female presented with an arteriovenous malformation (AVM) affecting the left paramedian frontoparietal hemisphere. Due to the proximity of her malformation to the thalamocortical and corticospinal tracts, she underwent GKS as she was not a candidate for surgical intervention. After receiving her first dose at 1600 cGy, her AVM persisted, and she continued to have symptoms. Roughly three years after her first dose, she underwent repeat SRS, receiving another 1600 cGy dose. The patient developed seizures eight months after this dose with new right-sided weakness and worsening headaches. MRI showed substantial edema and radiation necrosis.

HBO2 was initiated two weeks after her first seizure. She received eight sessions of hyperbaric oxygen therapy at 2.4 ATA for 90 minutes before her course was complicated by worsening headaches with seizures. A CT scan at that time showed no interval change. Hyperbaric oxygen treatment was continued at decreased pressure (2.0 ATA to reduce seizure risk from oxygen toxicity) for 32 more sessions for a total of 40. She continued dexamethasone during her hyperbaric course.

MRI after treatment showed improvement and the patient reported decreased severity in her headaches and less frequent seizures.

Case 2

A 39-year-old male with a left periventricular frontal lobe tangle of vessels. A fusiform dilated early enhancing left anterior caudate vein was identified that drained this left frontal AVM. He declined endovascular intervention, so he was treated with GKS and corticosteroids. He received 2000 cGy in one fraction. Before diagnosing the arteriovenous
Case Reports 19

malformation, the patient had a long history of vision problems and headaches. His vision had been progressively declining despite corrective lenses.

After his radiation therapy, the patient reported worsening headaches. Almost a year from GKS, imaging showed an enhancing left frontal lobe lesion, suggestive of radiation necrosis with mildly decreased surrounding edema/gliosis (Figure 1). Based on his diagnosis and imaging results, the patient was started on hyperbaric oxygen treatment at 2.0 ATA receiving 37 treatments of 90 minutes. He continued low-dose steroids throughout this course.

After therapy, follow-up MRI showed resolving necrotic changes from his radiation therapy with the lesion decreased in size (Figure 2). His headaches fully resolved, but he reported no changes in his vision.

**Case 3**

A 54-year-old female underwent resection of a craniopharyngioma followed by CyberKnife radiation at 700 cGy. This patient’s tumor recurred and was again treated with stereotactic radiation treatment, three rounds

<table>
<thead>
<tr>
<th>Age/Sex</th>
<th>Diagnosis</th>
<th>Radiation Treatment</th>
<th>Months between radiation and HBO2</th>
<th>HBO2* Pressure and # of treatments</th>
<th>Clinical Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 19F</td>
<td>Paramedian frontoparietal AVM</td>
<td>Gamma-Knife 3200 cGy</td>
<td>8</td>
<td>2.4 ATA x 8 à 2.0 ATA x 32</td>
<td>Improved headaches, decreased seizures</td>
</tr>
<tr>
<td>2 39M</td>
<td>Left periventricular AVM</td>
<td>Gamma-Knife 2000 cGy</td>
<td>11</td>
<td>2.0 ATA x 37</td>
<td>Resolved headaches, stable vision 20/50 OU</td>
</tr>
<tr>
<td>3 54F</td>
<td>Craniopharyngioma</td>
<td>CyberKnife 2100 cGy + IMRT 5040 cGy</td>
<td>53</td>
<td>2.0 ATA x 60</td>
<td>Vision returned to baseline</td>
</tr>
<tr>
<td>4 8F</td>
<td>WHO Grade III Astrocytoma</td>
<td>IMRT 5940 cGy</td>
<td>10</td>
<td>2.0 ATA x 40</td>
<td>Weaned off steroid with stable mass</td>
</tr>
<tr>
<td>5 44M</td>
<td>Traumatic brain injury, trigeminal neuralgia</td>
<td>CyberKnife 6000 cGy</td>
<td>23</td>
<td>2.0 ATA x 40</td>
<td>Improved sensation and vision</td>
</tr>
<tr>
<td>6 8F</td>
<td>Right cerebellar AVM</td>
<td>Gamma-Knife 1800 cGy</td>
<td>5</td>
<td>2.0 ATA x 40</td>
<td>Improved speech, eating, and walking</td>
</tr>
<tr>
<td>7 58M</td>
<td>Metastatic non-small squamous cell cancer to the right occipital lobe</td>
<td>IMRT 4000 cGy</td>
<td>79</td>
<td>2.0 ATA x 40</td>
<td>Improved Vision</td>
</tr>
<tr>
<td>8 41F</td>
<td>Right parietal AVM</td>
<td>Gamma-Knife 1800 cGy</td>
<td>13</td>
<td>2.4 ATA x 60</td>
<td>Increased sensation, improved mood, numbness</td>
</tr>
<tr>
<td>9 49F</td>
<td>Dural L occipital AVM</td>
<td>Gamma-Knife 4353 cGy</td>
<td>117</td>
<td>2.0 ATA x 29, then 30+10</td>
<td>Improved headaches and vision</td>
</tr>
<tr>
<td>10 49M</td>
<td>Right posterior thalamic AVM</td>
<td>Gamma-Knife 2000 cGy</td>
<td>11</td>
<td>2.0 ATA x 40</td>
<td>Increased range of motion of extremities, improved sensation. Persistent but markedly improved hemiplegia.</td>
</tr>
</tbody>
</table>

Note: HBO2 = hyperbaric oxygen treatment; *All treatments were 90 minutes plus compression/decompression time and air breaks (if indicated).

Figure 1. MRI prior to HBO2, roughly 19 months after completion of SRS. Enhancing left frontal lobe lesion with areas of restricted diffusion indicating radiation necrosis with mildly decreased surrounding edema/gliosis.

Figure 2. MRI roughly nine months after hyperbaric treatment. Decreased enhancing focus on the superior left frontal lobe with evidence of resolving surrounding vasogenic edema.
mass size on serial CT of the brain or increased symptoms. Although there was no improvement in symptoms, being able to discontinue steroids was a significant positive outcome.

**Case 5**
A 44-year-old-male sustained a traumatic brain injury with residual left-sided weakness and debilitating right-sided trigeminal neuralgia. He was treated with CyberKnife surgery at 6000 cGy in one treatment to the right trigeminal nerve. An MRI at that time was normal, with no lesions noted.

Roughly 23 months afterward, the patient developed left homonymous hemianopsia with episodes of confusion and muscle twitching. An MRI was suspicious for changes in the medial temporal lobe. Subsequent biopsies revealed only non-specific reactive gliosis. Following discussion with the neurosurgeons and neuroradiologists, the gliosis was felt to be soft tissue radionecrosis of the brain due to the delayed effects of his prior therapeutic radiation.

The patient received hyperbaric oxygen, 2.0 ATA for 40 treatments. The patient reported significant improvement in his visual fields, overall strength and denied any further periods of confusion. These were all identified as positive outcomes by the patient.

**Case 6**
An 8-year-old-female with a posterior AVM was treated with a ventriculostomy and embolization followed by resection. However, the patient presented with repeated episodes of incoordination afterward. MRI showed several left cerebral infarcts. The patient was treated with subsequent embolization followed by craniotomy and resections. Repeat MRI suggested a recurrent Martin Grade 3 AVM.

The patient then underwent Gamma Knife treatment at a single fraction of 1800 cGy (Figure 3). One-month post-radiation treatment, the patient began experiencing new cranial nerve palsy. Subsequent MRI findings demonstrated radiation-induced changes in the pons, with worsening necrosis over several months seen on serial imaging.

Hyperbaric oxygen was suggested for these radiation changes. She received 40 treatments at 2.0 ATA. Post-therapy, the patient showed improvements in speech, eating, and walking. Repeat MRI showed no significant changes but no evidence of arteriovenous malformation recurrence or progression.

**Case 7**
A 58-year-old-male with a history of non-small cell lung cancer with metastasis to the right occipital lobe was treated with craniotomy and whole-brain radiation. The patient received 20 fractions of IMRT totaling 4000 cGy. After radiation treatment, the patient developed progressive visual field defects over the years and some cognitive deficits.

The patient was treated at 2.0 ATA for 40 treatments with significant improvement in his vision.

**Case 8**
A 41-year-old-female with a history of a primary parenchymal hemorrhage likely due to cavernous or vascular malformations underwent stereotactic radiosurgery. She underwent a single fraction of stereotactic radiosurgery to a small right parietal AVM(1800 cGy). After her treatment, she developed subsequent weakness, numbness, and paresthesia in her lower extremities. MRI findings demonstrated vasogenic edema, midline shift, and signs of radiation necrosis due to delayed radiation injury.

Due to her persistent symptomology and history of stereotactic radiotherapy, the patient was referred for hyperbaric oxygen treatment one year post GKS. Her progression of symptoms stopped and started to improve by 20 treatments. She received 40 treatments at 2.4 ATA, followed by an additional 20 treatments due to ongoing improvement in her clinical symptoms. The patient noted improvement in her overall mood, weakness, and numbness in her extremities, and she regained the ability to do household chores and walk long distances.

**Case 9**
A 52-year-old female with a history of a left occipital dural AVM underwent embolization and GKS therapy. She developed progressive vision loss approximately seven years after radiation therapy. Hyperbaric oxygen therapy was initiated.

Initially, the patient planned to complete 40 treatment cycles. However, the patient developed severe headaches secondary to a newly developed radiation-induced cavernous malformation of the left occipital region and only completed 29. Seven years following this, she lost most of her peripheral vision, with increased edema and radionecrosis noted on MRI. Further hyperbaric oxygen therapy was started in conjunction with craniotomy to resect the remaining cavernous malformation. The patient tolerated the treatment well and showed definitive improvement of her headaches and vision after completing 30 pre-operative and ten postoperative treatments at 2.0 ATA.

**Case 10**
A 49-year-old male was found to have a Spetzler-Martin right posterior thalamic AVM. He underwent stereotactic radiosurgery with

---

**Figure 3.** Dose distribution of 1800 cGy at 100% of the isodose line.
initial improvement but developed left-sided hemiplegia eleven months afterward. MRI findings were suspicious for soft tissue radionecrosis. Following neurosurgical evaluation, hyperbaric oxygen therapy was started to reverse the delayed vascular effects of radiation injury.

The patient underwent 40 HBO2 treatments at 2.0 ATA. He reported considerable improvement in his extremities with a marked increase in range of motion and strength on his left side.

**Discussion**

SRS has grown into an important treatment option for various neurological diseases, including AVMs and certain central nervous system tumors. As patient survival improves, there has also been an increasing number of cases of cerebral necrosis secondary to SRS and radiation therapy. HBO2 is a viable treatment option for treating such radiation effects. Nevertheless, there is a paucity of cases regarding the use of hyperbaric oxygen in treating this complication. Leber et al. reported two patients with radionecrosis after GKS for AVMs. Both patients showed significant radiological improvement with HBO2. Kohshi et al. published a case report of a patient with resolved radiation necrosis after two rounds of HBO2. Chuba et al. reviewed a case series of ten pediatric patients treated with HBO2 after biopsy-confirmed radiation necrosis for various cerebral tumors. These patients had varying degrees of improvement, showing clinical recovery in some cases, with one case requiring reoperation for mass effect after initial improvement. Lynn et al. published a case report of with radiation-induced sequelae after SRS treatment for AVMs. The patient demonstrated significant improvement in his clinical symptoms and complete resolution of the AVM with minimal neurological deficits. Lastly, Valado et al. published a retrospective case series examining ten patients who underwent HBO2 after post-radiation injury to the central nervous system. In patients with radiation necrosis, HBO2 led to improvement in clinical and radiological outcomes. While these reports are promising, it is important to continue adding data to examine the role of HBO2 as a treatment option for future patients.

Currently, the only major therapy available to patients with radiation-induced cerebral injury is steroids, often accompanied by severe side effects and disadvantages. Steroids have a notable history of severe side effects and disadvantages, including tissue breakdown of radiotherapy. The two most common modalities of SRS are GKS and CyberKnife. The concept behind these modalities is simple, GKS concentrates beams from different angles in a precise spot within the central nervous system, allowing for a focused radiation dose. In contrast, CyberKnife radiotherapy uses adaptive image-guided radiation to track targets in both space and time. Compared to GKS, this technology allows CyberKnife patients to undergo radiotherapy in a frameless setting. Studies have shown fractionated CyberKnife therapy to be as effective and safe as single-fraction GKS for treating brain tumors, despite CyberKnife therapy having slightly inferior dosimetric properties. As CyberKnife therapy is relatively new, current literature in assessing the difference between these two forms of SRS are ongoing, including the rates of developing radionecrosis. Zhuang et al. have shown the dosimetric properties to be the most relevant factor in developing radionecrosis in CyberKnife therapies. Inoue et al. suggest the surrounding brain volume circumscribed within a single dose plays a more prominent role. In contrast, studies demonstrating tumor volume, in addition to dosimetric properties, are more relevant in predicting rates of radionecrosis in GKS. As there are no established standards to diagnose radionecrosis noninvasively, it is difficult to know when patients begin to develop this disease or if the irradiation method is relevant. Regardless, our case series illustrates clinical improvement of radionecrosis from IMRT in 2 cases, with fractionated CyberKnife therapy in 2 cases and GKS in 6 other cases. Most of the relevant literature focuses on the
role of HBO2 in cases of GKS. In the few reports of HBO2 used in CyberKnife surgeries, the therapy is compounded with other treatments, and its efficacy is labeled controversial. We demonstrate cases where HBO2 leads to clinical improvement regardless of radiation form.

Based on our experience, hyperbaric oxygen has the potential to be a standard protocol for radiation-induced central nervous system injury. We discuss ten patients with various doses and types of radiation across various ages; all cases demonstrated clinical improvement after HBO2. This case series adds to the few studies in the literature reiterating the role of HBO2 as a valuable therapeutic option for treating radiation-induced cerebral necrosis.

References